Zulong Sheng

547 total citations
24 papers, 429 citations indexed

About

Zulong Sheng is a scholar working on Molecular Biology, Cancer Research and Pharmacology. According to data from OpenAlex, Zulong Sheng has authored 24 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Cancer Research and 6 papers in Pharmacology. Recurrent topics in Zulong Sheng's work include Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). Zulong Sheng is often cited by papers focused on Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (5 papers) and Circular RNAs in diseases (4 papers). Zulong Sheng collaborates with scholars based in China, United States and Bangladesh. Zulong Sheng's co-authors include Yuyu Yao, Genshan Ma, Genshan Ma, Xiaodong Pan, Zhongpu Chen, Gaoliang Yan, Yefei Li, Yefei Li, Lijuan Chen and Zhi Zuo and has published in prestigious journals such as PLoS ONE, Biochemical and Biophysical Research Communications and Life Sciences.

In The Last Decade

Zulong Sheng

22 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zulong Sheng China 13 211 101 97 87 76 24 429
Yangguang Yin China 12 293 1.4× 80 0.8× 108 1.1× 53 0.6× 56 0.7× 20 550
Bin Zeng China 13 247 1.2× 64 0.6× 191 2.0× 61 0.7× 98 1.3× 22 516
Feng Cao China 8 232 1.1× 90 0.9× 70 0.7× 116 1.3× 59 0.8× 14 419
Olga Zhelyabovska United States 10 328 1.6× 67 0.7× 92 0.9× 114 1.3× 40 0.5× 12 541
Bingong Li China 11 198 0.9× 50 0.5× 82 0.8× 168 1.9× 43 0.6× 25 420
Ilaria Burba Italy 7 179 0.8× 109 1.1× 72 0.7× 57 0.7× 31 0.4× 10 352
Mariangela Scalise Italy 17 371 1.8× 103 1.0× 228 2.4× 176 2.0× 39 0.5× 29 698
Qin Yi China 16 313 1.5× 130 1.3× 70 0.7× 33 0.4× 36 0.5× 42 510
Sufen Guo China 14 257 1.2× 143 1.4× 91 0.9× 51 0.6× 34 0.4× 16 391

Countries citing papers authored by Zulong Sheng

Since Specialization
Citations

This map shows the geographic impact of Zulong Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zulong Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zulong Sheng more than expected).

Fields of papers citing papers by Zulong Sheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zulong Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zulong Sheng. The network helps show where Zulong Sheng may publish in the future.

Co-authorship network of co-authors of Zulong Sheng

This figure shows the co-authorship network connecting the top 25 collaborators of Zulong Sheng. A scholar is included among the top collaborators of Zulong Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zulong Sheng. Zulong Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Xiaodong, Zhuyuan Liu, Zulong Sheng, et al.. (2025). METTL3 Silencing Suppresses Cardiac Fibrosis Post Myocardial Infarction via m6A Modification of SMOC2. Journal of Cellular and Molecular Medicine. 29(17). e70829–e70829.
3.
Yan, Gaoliang, Renhua Sun, Zhongpu Chen, et al.. (2021). PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells. Drug Design Development and Therapy. Volume 15. 2025–2033. 10 indexed citations
4.
Zhu, Yinghong, Yongjun Li, Zhi Zuo, et al.. (2020). Protease-activated receptor 2 deficiency in hematopoietic lineage protects against myocardial infarction through attenuated inflammatory response and fibrosis. Biochemical and Biophysical Research Communications. 526(1). 253–260. 11 indexed citations
5.
Ma, Genshan, Zulong Sheng, Qingjie Wang, et al.. (2020). MSCs Contribute to the Conversion of Ly6Chigh Monocytes into Ly6Clow Subsets under AMI. Stem Cells International. 2020. 1–10. 5 indexed citations
6.
Chen, Zhongpu, Xiaodong Pan, Gaoliang Yan, Zulong Sheng, & Genshan Ma. (2020). miR-142 is a Sensitive Biomarker for the Diagnosis and Prognosis of Acute Myocardial Infarction. Clinical Laboratory. 66(06/2020). 6 indexed citations
7.
Zuo, Zhi, et al.. (2019). Tetramethylprazine attenuates myocardial ischemia/reperfusion injury through modulation of autophagy. Life Sciences. 239. 117016–117016. 28 indexed citations
8.
Chen, Zhongpu, Xiaodong Pan, Zulong Sheng, et al.. (2019). miR-17 regulates the proliferation and apoptosis of endothelial cells in coronary heart disease via targeting insulin-like-growth factor 1. Pathology - Research and Practice. 215(9). 152512–152512. 17 indexed citations
9.
Li, Bing, et al.. (2018). Kallistatin Inhibits Atherosclerotic Inflammation by Regulating Macrophage Polarization. Human Gene Therapy. 30(3). 339–351. 29 indexed citations
10.
Sheng, Zulong, Qiuyun Wang, Yongjun Li, et al.. (2018). Advanced glycation end products of bovine serum albumin affect the cell growth of human umbilical vein endothelial cells via modulation of MEG3/miR-93/p21 pathway. Acta Biochimica et Biophysica Sinica. 51(1). 41–50. 6 indexed citations
11.
Sun, Yuning, et al.. (2018). DNA methylation regulates α‐smooth muscle actin expression during cardiac fibroblast differentiation. Journal of Cellular Physiology. 234(5). 7174–7185. 31 indexed citations
12.
Sheng, Zulong, Yuyu Yao, Yefei Li, Cong Fu, & Genshan Ma. (2015). Transplantation of bradykinin-preconditioned human endothelial progenitor cells improves cardiac function via enhanced Akt/eNOS phosphorylation and angiogenesis.. PubMed. 7(6). 1045–26. 13 indexed citations
13.
Sheng, Zulong, et al.. (2013). Bradykinin Preconditioning Improves Therapeutic Potential of Human Endothelial Progenitor Cells in Infarcted Myocardium. PLoS ONE. 8(12). e81505–e81505. 25 indexed citations
14.
Yao, Yuyu, Zulong Sheng, Yefei Li, et al.. (2013). Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Laboratory Investigation. 93(5). 577–591. 18 indexed citations
15.
Yao, Yuyu, Zulong Sheng, Yefei Li, et al.. (2012). Tissue Kallikrein Promotes Cardiac Neovascularization by Enhancing Endothelial Progenitor Cell Functional Capacity. Human Gene Therapy. 23(8). 859–870. 22 indexed citations
16.
Yao, Yuyu, Yuanyuan Wang, Yi Zhang, et al.. (2012). In Vivo Imaging of Macrophages during the Early-Stages of Abdominal Aortic Aneurysm Using High Resolution MRI in ApoE−/− Mice. PLoS ONE. 7(3). e33523–e33523. 26 indexed citations
17.
Yao, Yuyu, et al.. (2012). Hypoxic Preconditioning Improves Survival of Cardiac Progenitor Cells: Role of Stromal Cell Derived Factor-1α–CXCR4 Axis. PLoS ONE. 7(7). e37948–e37948. 61 indexed citations
18.
Ren, Liqun, Naifeng Liu, Hong Zhi, et al.. (2011). Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovascular Diabetology. 10(1). 10–10. 12 indexed citations
19.
Li, Yefei, et al.. (2011). Dual-modal tracking of transplanted mesenchymal stem cells after myocardial infarction. International Journal of Nanomedicine. 6. 815–815. 24 indexed citations
20.
Ren, Liqun, Yingjuan Li, Yanzhi Li, et al.. (2009). The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin‐angiotensin system in diet‐induced hypercholesterolemic rats. Cell Biochemistry and Function. 28(1). 58–65. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026